KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Astellas Pharma Inc
Tizona Therapeutics, Inc
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
BioAtla, Inc.
Pfizer
Sanofi
Blokhin's Russian Cancer Research Center
University of California, San Diego